Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075562 | 1.00 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL30350412 | 1.00 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL3032275 | 0.93 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL10074634 | 0.89 | DRD2 (0.79) | DRD2DRD3 | |
| SCHEMBL7883530 | 0.89 | DRD2 (0.79) | DRD2DRD3 | |
| SCHEMBL3029994 | 0.87 | DRD2 (0.76) | DRD2DRD3 | |
| SCHEMBL3289819 | 0.87 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL2699679 | 0.84 | DRD2 (0.72) | DRD2DRD3 | |
| SCHEMBL10075561 | 0.83 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL2700834 | 0.83 | DRD2 (0.76) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117148-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENTS OF IMMUNE RELATED DISEASES AND DISORDERS | HOLMAN ANDREW J (US) | 2018-05-03 | — | — | US | claimed |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-11-07 | — | — | US | disclosed |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230312510-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIVERSITY OF DELHI (IN) | 2023-10-05 | — | — | US | disclosed |
| EP-4178564-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | The McLean Hospital Corporation (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-115843247-A | Compounds and methods for treating neurodegenerative diseases | 麦克莱恩医院公司 | 2023-03-24 | — | — | CN | disclosed |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3971178-A1 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | The McLean Hospital Corporation (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-02-24 | — | — | US | disclosed |
| WO-2022010984-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE MCLEAN HOSPITAL CORPORATION (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20140294855-A1 | SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2013134047-A2 | AMINOQUINOLINE DERIVATIVES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2012174537-A2 | SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-12-20 | — | — | WO | disclosed |
| US-8227604-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2012-07-24 | — | — | US | disclosed |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | WAYNE STATE UNIVERSITY (US) | 2010-08-19 | — | — | US | disclosed |
| US-7723519-B2 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2009056811-A2 | MEDICAMENTS | MOTAC NEUROSCIENCE LIMITED (GB) | 2009-05-07 | — | — | WO | disclosed |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| US-6982332-B2 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering CNS activity | WAYNE STATE UNIVERSITY (US) | 2006-01-03 | — | — | US | disclosed |
| US-20030195219-A1 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity | WAYNE STATE UNIVERSITY | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312510-A1 | COMPOUNDS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NCOR1, NLN, NCOR2 | DRD2 2706/4885DRD3 2951/4885 |
| US-20030195219-A1 | Hybrid 2-aminotetralin and aryl-substituted piperazine compounds and their use in altering cns activity | HTR3A, HTR3C, HTR2C | DRD2 5/4885DRD3 7/4885 |
| US-20100210663-A1 | Hybrid 2-Aminotetralin and Aryl-Substituted Piperazine Compounds and their Use in Altering CNS Activity | HTR3A, HTR3C, HTR2C | DRD2 5/4885DRD3 7/4885 |
| US-20220054499-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | DRD2 4820/4885DRD3 4812/4885 |
| US-20240366627-A1 | SMALL MOLECULES FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | DRD2 4820/4885DRD3 4812/4885 |
| US-11963964-B2 | Small molecules for mouse satellite cell proliferation | MKI67, MYLK2, MYH2 | DRD2 4820/4885DRD3 4812/4885 |
| US-20060020132-A1 | Hybrid 2-aminoterailin and aryl-substituted piperazine compounds and their use in altering CNS activity | HTR3A, DRD3, DRD2 | DRD2 3/4885DRD3 2/4885 |
| US-20140294855-A1 | SMALL MOLECULE SCREENING FOR MOUSE SATELLITE CELL PROLIFERATION | MKI67, MYLK2, MYH2 | DRD2 4801/4885DRD3 4768/4885 |
| US-11426400-B2 | Methods of increasing satellite cell proliferation with vorinostat or bosutinib | MKI67, CDK4, CDKN1A | DRD2 4871/4885DRD3 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.